Sustained virologic response to second-generation direct-acting antivirals for Hepatitis C

Bibliographic Details
Main Author: Compri, Adriana Parise
Publication Date: 2020
Other Authors: Silva, Vanessa Cristina Martins, Lemos, Marcilio Figueiredo, Oba, Isabel Takano, Moreira, Regina Célia
Format: Article
Language: por
Source: BEPA. Boletim epidemiológico paulista (Online)
Download full: https://periodicos.saude.sp.gov.br/BEPA182/article/view/33949
Summary: Background: Recently, the management of patients chronically infected with the hepatitis C virus has progressed, including second generation direct-acting antivirals (DAA) that have potential to clear infection in most patients, especially genotype 1-infected patients. Objectives: Evaluate the sustained virologic response (SVR) of Hepatitis C treatment with second-generation DAAs made available by the Ministry of Health in follow-up patients of a São Paulo health service. Methods: This was a retrospective observational study, based on secondary data obtained from GAL and MEDEX systems. Briefly, 615 convenience samples were analyzed of patients who underwent second-generation DAAs treatment from June 2016 to April 2018. Demographic and clinical data were also analyzed. Results: SVR was observed in 600 treated patients (97.6%). Further, 98.4% and 94.7% of genotype 1 and genotype 3 patients, respectively, responded to treatment (P = 0.02). Among patients who did not respond to treatment, 93.3% were male, naive treatment and were treated for 12 weeks, except one genotype 1, HIV-coinfected patient who received treatment for 24 weeks. Conclusions: A high rate of SVR was found for Hepatitis C treatment with second-generation DAAs. SVR was significantly reduced in male and genotype 3-infected patients, although it still exceeded 90%. Further, HIV coinfection showed no association with reduced SVR rates (p=0.98).
id SESSP_5a19f00829e0da3b52cab80e8e35014e
oai_identifier_str oai:ojs.periodicos.saude.sp.gov.br:article/33949
network_acronym_str SESSP
network_name_str BEPA. Boletim epidemiológico paulista (Online)
repository_id_str
spelling Sustained virologic response to second-generation direct-acting antivirals for Hepatitis CResposta virológica sustentada às drogas de ação direta de segunda geração para hepatite CHepatite C crônicaEstudo observacionaTratamentoGenótipoResposta virológica sustentadaChronic Hepatitis CObservational studyTreatmentGenotypeSustained virologic responseBackground: Recently, the management of patients chronically infected with the hepatitis C virus has progressed, including second generation direct-acting antivirals (DAA) that have potential to clear infection in most patients, especially genotype 1-infected patients. Objectives: Evaluate the sustained virologic response (SVR) of Hepatitis C treatment with second-generation DAAs made available by the Ministry of Health in follow-up patients of a São Paulo health service. Methods: This was a retrospective observational study, based on secondary data obtained from GAL and MEDEX systems. Briefly, 615 convenience samples were analyzed of patients who underwent second-generation DAAs treatment from June 2016 to April 2018. Demographic and clinical data were also analyzed. Results: SVR was observed in 600 treated patients (97.6%). Further, 98.4% and 94.7% of genotype 1 and genotype 3 patients, respectively, responded to treatment (P = 0.02). Among patients who did not respond to treatment, 93.3% were male, naive treatment and were treated for 12 weeks, except one genotype 1, HIV-coinfected patient who received treatment for 24 weeks. Conclusions: A high rate of SVR was found for Hepatitis C treatment with second-generation DAAs. SVR was significantly reduced in male and genotype 3-infected patients, although it still exceeded 90%. Further, HIV coinfection showed no association with reduced SVR rates (p=0.98).Introdução: Recentemente, o manejo de pacientes infectados cronicamente pelo vírus da Hepatite C tem progredido, incluindo os antivirais de ação direta (DAAs) de segunda geração, que têm potencial de clarear a infecção em muitos pacientes, especialmente naqueles infectados pelo genótipo 1. Objetivo: Avaliar a resposta virológica sustentada (RVS) ao tratamento para Hepatite C com as drogas de ação direta (DAA) de segunda geração, disponibilizados pelo Ministério da Saúde em pacientes acompanhados por um serviço de saúde da cidade de São Paulo. Métodos: Estudo retrospectivo observacional, baseado em dados secundários obtidos dos sistemas GAL e MEDEX. Foram analisadas 615 amostras de conveniência de pacientes que realizaram tratamento com os DAA de segunda geração no período de junho de 2016 a abril de 2018. Os dados demográficos e clínicos também foram analisados. Resultados: RVS foi observada em 600 pacientes (97,6%). Além disso, 98,4% e 94,7% dos pacientes genótipo 1 e 3, respectivamente, responderam ao tratamento (P = 0.02). Dentre os pacientes que não responderam ao tratamento, 93,3% eram do sexo masculino, virgens de tratamento, e foram tratados por 12 semanas, exceto 1 paciente genótipo 1 e coinfectado com HIV que tratou por 24 semanas. Conclusão: A alta taxa de RVS foi observada para tratamento da Hepatite C com os DAA de segunda geração. A RVS foi significativamente reduzida em pacientes do sexo masculino e infectados pelo genótipo 3, apesar de ainda ser superior a 90%. A coinfecção com o HIV não demonstrou associação com a redução das taxas de RVS (p=0,98).Coordenadoria de Controle de Doenças - Secretaria de Estado da Saúde de São Paulo2020-04-30info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionAvaliado pelos paresapplication/pdfhttps://periodicos.saude.sp.gov.br/BEPA182/article/view/3394910.57148/bepa.2020.v.17.33949BEPA. Boletim Epidemiológico Paulista; Vol. 17 No. 196 (2020); 3-12BEPA. Boletim Epidemiológico Paulista; Vol. 17 Núm. 196 (2020); 3-12BEPA. Boletim Epidemiológico Paulista ; v. 17 n. 196 (2020); 3-121806-42721806-423Xreponame:BEPA. Boletim epidemiológico paulista (Online)instname:Secretaria de Estado da Saúde de São Paulo (SES-SP)instacron:SESSPporhttps://periodicos.saude.sp.gov.br/BEPA182/article/view/33949/32728Copyright (c) 2020 Adriana Parise Compri, Vanessa Cristina Martins Silva, Marcilio Figueiredo Lemos, Isabel Takano Oba, Regina Célia Moreirainfo:eu-repo/semantics/openAccessCompri, Adriana PariseSilva, Vanessa Cristina MartinsLemos, Marcilio FigueiredoOba, Isabel TakanoMoreira, Regina Célia2023-11-08T14:20:41Zoai:ojs.periodicos.saude.sp.gov.br:article/33949Revistahttps://periodicos.saude.sp.gov.br/BEPA182/indexPUBhttps://periodicos.saude.sp.gov.br/BEPA182/oaibepa@saude.sp.gov.br | periodicossp@saude.sp.gov.brhttps://doi.org/10.57148/bepa1806-42721806-423Xopendoar:2023-11-08T14:20:41BEPA. Boletim epidemiológico paulista (Online) - Secretaria de Estado da Saúde de São Paulo (SES-SP)false
dc.title.none.fl_str_mv Sustained virologic response to second-generation direct-acting antivirals for Hepatitis C
Resposta virológica sustentada às drogas de ação direta de segunda geração para hepatite C
title Sustained virologic response to second-generation direct-acting antivirals for Hepatitis C
spellingShingle Sustained virologic response to second-generation direct-acting antivirals for Hepatitis C
Compri, Adriana Parise
Hepatite C crônica
Estudo observaciona
Tratamento
Genótipo
Resposta virológica sustentada
Chronic Hepatitis C
Observational study
Treatment
Genotype
Sustained virologic response
title_short Sustained virologic response to second-generation direct-acting antivirals for Hepatitis C
title_full Sustained virologic response to second-generation direct-acting antivirals for Hepatitis C
title_fullStr Sustained virologic response to second-generation direct-acting antivirals for Hepatitis C
title_full_unstemmed Sustained virologic response to second-generation direct-acting antivirals for Hepatitis C
title_sort Sustained virologic response to second-generation direct-acting antivirals for Hepatitis C
author Compri, Adriana Parise
author_facet Compri, Adriana Parise
Silva, Vanessa Cristina Martins
Lemos, Marcilio Figueiredo
Oba, Isabel Takano
Moreira, Regina Célia
author_role author
author2 Silva, Vanessa Cristina Martins
Lemos, Marcilio Figueiredo
Oba, Isabel Takano
Moreira, Regina Célia
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Compri, Adriana Parise
Silva, Vanessa Cristina Martins
Lemos, Marcilio Figueiredo
Oba, Isabel Takano
Moreira, Regina Célia
dc.subject.por.fl_str_mv Hepatite C crônica
Estudo observaciona
Tratamento
Genótipo
Resposta virológica sustentada
Chronic Hepatitis C
Observational study
Treatment
Genotype
Sustained virologic response
topic Hepatite C crônica
Estudo observaciona
Tratamento
Genótipo
Resposta virológica sustentada
Chronic Hepatitis C
Observational study
Treatment
Genotype
Sustained virologic response
description Background: Recently, the management of patients chronically infected with the hepatitis C virus has progressed, including second generation direct-acting antivirals (DAA) that have potential to clear infection in most patients, especially genotype 1-infected patients. Objectives: Evaluate the sustained virologic response (SVR) of Hepatitis C treatment with second-generation DAAs made available by the Ministry of Health in follow-up patients of a São Paulo health service. Methods: This was a retrospective observational study, based on secondary data obtained from GAL and MEDEX systems. Briefly, 615 convenience samples were analyzed of patients who underwent second-generation DAAs treatment from June 2016 to April 2018. Demographic and clinical data were also analyzed. Results: SVR was observed in 600 treated patients (97.6%). Further, 98.4% and 94.7% of genotype 1 and genotype 3 patients, respectively, responded to treatment (P = 0.02). Among patients who did not respond to treatment, 93.3% were male, naive treatment and were treated for 12 weeks, except one genotype 1, HIV-coinfected patient who received treatment for 24 weeks. Conclusions: A high rate of SVR was found for Hepatitis C treatment with second-generation DAAs. SVR was significantly reduced in male and genotype 3-infected patients, although it still exceeded 90%. Further, HIV coinfection showed no association with reduced SVR rates (p=0.98).
publishDate 2020
dc.date.none.fl_str_mv 2020-04-30
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Avaliado pelos pares
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://periodicos.saude.sp.gov.br/BEPA182/article/view/33949
10.57148/bepa.2020.v.17.33949
url https://periodicos.saude.sp.gov.br/BEPA182/article/view/33949
identifier_str_mv 10.57148/bepa.2020.v.17.33949
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://periodicos.saude.sp.gov.br/BEPA182/article/view/33949/32728
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Coordenadoria de Controle de Doenças - Secretaria de Estado da Saúde de São Paulo
publisher.none.fl_str_mv Coordenadoria de Controle de Doenças - Secretaria de Estado da Saúde de São Paulo
dc.source.none.fl_str_mv BEPA. Boletim Epidemiológico Paulista; Vol. 17 No. 196 (2020); 3-12
BEPA. Boletim Epidemiológico Paulista; Vol. 17 Núm. 196 (2020); 3-12
BEPA. Boletim Epidemiológico Paulista ; v. 17 n. 196 (2020); 3-12
1806-4272
1806-423X
reponame:BEPA. Boletim epidemiológico paulista (Online)
instname:Secretaria de Estado da Saúde de São Paulo (SES-SP)
instacron:SESSP
instname_str Secretaria de Estado da Saúde de São Paulo (SES-SP)
instacron_str SESSP
institution SESSP
reponame_str BEPA. Boletim epidemiológico paulista (Online)
collection BEPA. Boletim epidemiológico paulista (Online)
repository.name.fl_str_mv BEPA. Boletim epidemiológico paulista (Online) - Secretaria de Estado da Saúde de São Paulo (SES-SP)
repository.mail.fl_str_mv bepa@saude.sp.gov.br | periodicossp@saude.sp.gov.br
_version_ 1838465355713871872